United States

MD Anderson Moon Shots Program begins to generate innovations

Friday, October 31, 2014 02:07 PM

Improved surgical outcomes for ovarian cancer, expanded potential impact for new drugs and a novel family outreach program to head off cancers fueled by known genetic risk mutations are among the early innovations of the University of TexasMD Anderson Cancer Center's Moon Shots Program.

More... »


Cytomedix re-brands as Nuo Therapeutics

Friday, October 31, 2014 02:05 PM

Cytomedix, a Gaithersburg, Md.-based pioneer in biodynamic therapies, has launched its new corporate brand identity, Nuo Therapeutics. The company intends to change its corporate name to Nuo Therapeutics, following shareholder approval of the name change proposal at its Annual General Meeting of the company's shareholders on Nov. 12.

More... »


Paratek Pharmaceuticals completes merger with Transcept Pharmaceuticals

Friday, October 31, 2014 02:04 PM

Boston-based Paratek Pharmaceuticals and Transcept Pharmaceuticals, based in California, have completed their merger. Transcept changed its name to Paratek Pharmaceuticals.

More... »

BloodCenter of Wisconsin launches next-generation sequencing HemeOnc Panel

Thursday, October 30, 2014 12:22 PM

BloodCenter of Wisconsin's Diagnostic Laboratories has announced the availability of a comprehensive cancer mutation HemeOnc Panel using next-generation sequencing (NGS) technology. The NGS panel is designed to detect variants in 30 genes that are either prognostic or diagnostic for 10 different myeloid hematologic malignancies.

More... »

Booz Allen Hamilton acquires Epidemico

Thursday, October 30, 2014 12:15 PM

Booz Allen Hamilton, a Boston, Mass.-based provider of management consulting, technology and engineering services, has acquired Epidemico, a Boston informatics company.

More... »

U.S. government institutes funding pause on gain-of-function research

Wednesday, October 29, 2014 01:39 PM

The U.S. government will undertake a deliberative process to assess the risks and benefits of certain gain-of-function (GOF) experiments with influenza, SARS and MERS viruses in order to develop a new federal policy regarding the funding of this research, announced Francis S. Collins, M.D., Ph.D., NIH director, in a statement. U.S. government agencies will institute a pause on the funding of any new studies involving these experiments.

More... »

Cepheid, FIND, Rutgers collaborate on Xpert MTB/RIF test

Wednesday, October 29, 2014 01:22 PM

Cepheid, a Sunnyvale, Calif.-based molecular diagnostics company, FIND, a Switzerland-based international nonprofit organization and Rutgers New Jersey Medical School are collaborating to develop Xpert MTB/RIF Ultra, a next-generation test for Mycobacterium tuberculosis (TB) with increased sensitivity to aid in detection of patients with smear-negative TB, which often is associated with HIV co-infection. The collaboration also is receiving additional support from the National Institute of Allergy and Infectious Diseases at the NIH.

More... »

NIH launches Illuminating the Druggable Genome to find potential drug targets

Wednesday, October 29, 2014 01:09 PM

NIH has announced a new collaborative initiative to improve human health by exploring poorly understood genes that have the potential to be modified by medicines. The effort is part of an NIH Common Fund three-year pilot project called Illuminating the Druggable Genome (IDG). For the initial phase of the program, NIH has allocated $5.8 million to eight institutions and for intramural resources.

More... »

PharmaTimes launches 2015 Clinical Researcher of the Year competition

Wednesday, October 29, 2014 08:21 AM

The 2015 PharmaTimes Clinical Researcher of the Year-The Americas competition is open for entry. All research professionals are encouraged to enter.

More... »

Burzynski Research Institute to launch diffuse intrinsic brainstem glioma trial

Monday, October 27, 2014 01:38 PM

Burzynski Research Institute (BRI) has announced that the FDA has given the company permission to conduct an open-label study of Antineoplastons A10 and AS2-1 in patients >3 months of age with a diffuse intrinsic brainstem glioma (DIPG).

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs